Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib

Category	Detail
Condition	Acute coronary syndrome (ACS) survivors at risk of subsequent myocardial infarction (MI)
Key Mechanisms	Risk prediction based on clinical, biochemical, and genetic markers including LDL-C, blood pressure, A1c, hs-C-reactive protein, smoking, age, and ADCY9 genotype; pharmacogenetic response to dalcetrapib
Target Population	Patients clinically stable 1–3 months after recent ACS, including those with AA genotype at rs1967309 in ADCY9 gene
Care Setting	Post-ACS secondary prevention in outpatient cardiology and clinical trial settings

A prediction index incorporating 18 baseline variables predicts future MI with good accuracy (Harrell C-index 0.72) in ACS survivors.
Prior coronary events, LDL-C, blood pressure, A1c, hs-C-reactive protein, smoking, and age are significant contributors to MI risk despite guideline-directed therapy.
Dalcetrapib reduces MI risk by 23% in patients with the AA genotype at rs1967309 in ADCY9, independent of other risk factors.

Assess traditional risk factors including prior coronary events, LDL-C, blood pressure, glycemic control (A1c), inflammation (hs-C-reactive protein), smoking status, and age in ACS survivors.
Consider genotyping for rs1967309 in ADCY9 gene to identify patients who may benefit from dalcetrapib.

Continue guideline-directed secondary prevention therapies post-ACS.
In patients with AA genotype at rs1967309, consider dalcetrapib as an adjunct to reduce MI risk.
Address modifiable risk factors such as LDL-C, blood pressure, glycemic control, and smoking cessation.

Regularly monitor LDL-C, blood pressure, A1c, and hs-C-reactive protein levels to assess ongoing risk and treatment efficacy.
Monitor for recurrent cardiovascular events in ACS survivors.

Despite intensive secondary prevention, residual risk of MI remains influenced by prior events and on-treatment risk factors.
Pharmacogenetic variability affects response to dalcetrapib; non-AA genotype patients may not derive the same benefit.

ACS survivors clinically stable 1–3 months post-event, specifically those with AA genotype at rs1967309 in ADCY9 gene

Dalcetrapib 600 mg daily reduces MI risk by 23% compared to placebo in genetically defined responders, independent of traditional risk factors.

Incorporate comprehensive risk assessment using clinical, biochemical, and genetic markers to stratify MI risk post-ACS.
Use pharmacogenetic testing to guide personalized secondary prevention strategies with dalcetrapib.
Maintain aggressive control of LDL-C, blood pressure, glycemic status, and inflammation markers to reduce residual MI risk.
Continue smoking cessation support as a critical component of secondary prevention.

Clinical Scorecard: Predicting Future Myocardial Infarction Risk in Acute Coronary Syndrome Survivors: Insights from Pharmacogenetic Responses to Dalcetrapib